Evidence map›Paper›PMID 36836433›Full record

ArticleJournal of personalized medicine2023

Quantification of Extracellular Volume in CT in Neoadjuvant Chemotherapy in Breast Cancer: New Frontiers in Assessing the Cardiotoxicity of Anthracyclines and Trastuzumab.

Marcello Chiocchi, Martina Cerocchi, Federica Di Tosto, Roberto Rosenfeld, Monia Pasqualetto, Gianluca Vanni, Vincenzo De Stasio, Luca Pugliese, Carlo Di Donna, Gaetano Idone and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Neoadjuvant chemotherapy and perioperative cardiotoxicity.Journal of anesthesia and translational medicine · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Marcello ChiocchiDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Martina CerocchiDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Federica Di TostoDepartment of Diagnostic Imaging and Interventional Radiology, Ospedale Fatebenefratelli Isola Tiberina-Gemelli Isola, 00186 Rome, Italy.
Roberto RosenfeldMedical Oncology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0003-2381-4237
Monia PasqualettoDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Gianluca VanniBreast Unit, Department of Surgical Science, University of Rome "Tor Vergata", 00133 Rome, Italy.
Vincenzo De StasioDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Luca PuglieseDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Carlo Di DonnaDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Gaetano IdoneUnit of Cardiology, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Saverio MuscoliUnit of Cardiology, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-4037-7561
Ilaria PortarenaMedical Oncology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.
Mario RoselliMedical Oncology Unit, Department of Systems Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-2431-6689
Francesco GaraciDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
Roberto FlorisDepartment of Biomedicine and Prevention, Division of Diagnostic Imaging, University of Rome "Tor Vergata", 00133 Rome, Italy.
University of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer patients undergoing neoadjuvant chemotherapy with anthracyclines or trastuzumab can suffer cardiotoxic issues. Nowadays, the markers of cardiac damage are still not reliable, and extracellular volume (ECV) calculated from CT could be a promising cardiotoxic marker. Eighty-two patients, treated with two different chemotherapy regimens based on doxorubicin (DOX) or epirubicin-trastuzumab (EPI-TRAS), were retrospectively selected and the variations in extracellular volume (ECV) values were measured and analyzed. Whole Body CT (WB-CT) scans were acquired after 1 min, in the portal phase (PP), and after 5 min, in the delayed phases (DP), at the baseline (T

Indexed as

cardiotoxicitychemotherapyextracellular volume

Identifiers

PMID36836433
PMCPMC9960372
OpenAlexW4317810572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.